Of the patients taking LEQEMBI, 16% were ApoE ε4 homozygotes, 53% were heterozygotes, and 31% were noncarriers. With LEQEMBI, ARIA was higher in ApoE ε4 homozygotes (LEQEMBI: 45%; placebo ...

But in just the past year and a half, two anti-amyloid drugs—lecanemab (Leqembi) and donanemab (Kisunla ... And remember that APOE e4 gene? Having two copies also boosts the risk of ARIA. So before ...

Specifically, your doctor will monitor your scans for amyloid-related imaging abnormalities (ARIA). This is because Leqembi treatment can cause ARIA. In fact, Leqembi has a boxed warning about the ...

The first full regulatory approval for an amyloid-targeting therapy for Alzheimer’s disease could come within a month, after an expert panel voted 6 to 0 in favour of Eisai and Biogen’s Leqembi.

Eisai Europe Ltd. and Biogen Idec Ltd. announced that NICE will convene a third appraisal committee meeting for the ongoing evaluation of Leqembi® (lecanemab ... in adult patients who are ...

A second, somewhat less controversial, anti-amyloid agent gained approval in January 2023: lecanemab (Leqembi ... serious ARIA subsequently died, two of whom were heterozygous APOE carriers ...

The milestone was reached as sales of Leqembi reached €200 million in Eisai fiscal year 2024 (April 2024 - Match 2025). The event entitles BioArctic to a €10 million payment. Leqembi is the ...

Fatal events of ICH in patients taking LEQEMBI have been observed. Risk Factors of ARIA and ICH ApoE ε4 Carrier Status Of the patients taking LEQEMBI, 16% were ApoE ε4 homozygotes, 53% were ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with ...